Merck (MRK) stock achieved a 5-day winning streak, with total gains during this time reaching 6.9%. The company’s market ...

Merck (MRK) closed at $106.45 in the latest trading session, marking a +1.34% move from the prior day. This change outpaced the S&P 500's 0.32% gain on the day. Elsewhere, the Dow saw an upswing of 0.

The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look more into that and determine whether now is a good time to buy shares.

Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few ...

Pfizer & Merck are the boring intentional reset w/flat growth expectations. Pfizer now offers high dividends, Merck offers ...

FDA plans to fast-track reviews of two experimental Merck drugs under its priority voucher program, potentially accelerating ...

The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's cholesterol pill ...

The White House announced Friday that nine additional pharmaceutical companies have agreed to follow President Trump’s “most ...